Calcitonin as an adjunct for phantom limb pain.

Area of Science:

• Pain Management
• Neuropeptide Hormone Research
• Post-Amputation Care

Background:

• Phantom limb pain (PLP) is a common and challenging complication following lower limb amputation.
• Current management strategies for PLP have limitations, necessitating exploration of novel therapeutic adjuncts.
• Calcitonin, a naturally occurring hormone, has shown potential in modulating pain pathways.

Purpose of the Study:

• To evaluate the efficacy of calcitonin as an adjunctive therapy for reducing phantom limb pain (PLP) in patients who have undergone lower limb amputation.
• To assess the impact of calcitonin on pain intensity, pain-related distress, and patient-reported pain relief.
• To compare the effectiveness of calcitonin in patients with and without diabetes.

Main Methods:

• Retrospective analysis of 35 patients receiving at least 3 days of calcitonin treatment for PLP post-lower limb amputation.
• Collection of demographic data and pain ratings (intensity, distress, activity interference) before and after calcitonin intervention.
• Statistical analysis using descriptive statistics, paired t-tests, and two-way repeated measures ANOVA to compare outcomes, including Cohen's d for effect size.

Main Results:

• Calcitonin treatment significantly reduced mean pain intensity (6.41 to 5.24, p=0.02) and pain-related distress (5.85 to 4.81, p=0.014).
• Patient-reported pain relief scores significantly increased from 33.69 to 58.21 (p=0.035).
• No significant differences in pain reduction were observed between diabetic and non-diabetic patients, and no change in opioid use was noted.

Conclusions:

• Calcitonin serves as an effective adjunct therapy for alleviating phantom limb pain (PLP) following lower limb amputation.
• The therapy significantly decreases pain intensity and distress while enhancing patient-perceived pain relief.
• The beneficial effects of calcitonin on PLP are consistent across both diabetic and non-diabetic patient populations.